BridgeLine Translational Partners
Strategy Built to Survive Diligence and Accelerate the Path to the Clinic.
We help early-stage biotech companies figure out which preclinical studies to run, in what order, and build the evidence package that survives investor scrutiny and pharma BD diligence.
Complimentary. 30 minutes. No obligation.
What We Do
Three connected capabilities, all rooted in preclinical expertise.
Preclinical Strategy
Figure out which studies to run, in what order, with what criteria for success. Build a development plan with timelines, budgets, and CRO recommendations that satisfies regulatory expectations and convinces investors. When the program reaches IND stage, we write the nonclinical sections of your regulatory documents.
Portfolio Strategy
Evaluate each program as a total opportunity: scientific rationale, competitive landscape, commercial potential, and development feasibility. Recommend which programs to advance, which to pause, and where to concentrate resources based on the full strategic picture.
Investor and Partner Readiness
Evaluate the total opportunity the way an investor or pharma BD team would: the science, the market, the competitive positioning, and the development plan. Find the gaps in the story, not just the data, and fix them before diligence.
How We Work
A simple path from first conversation to deliverable.
Strategy Call
Complimentary · 30 minutes
Book a complimentary call. Tell us what’s keeping you up at night. We’ll listen, ask the right questions, and tell you how we can help. No cost. No obligation.
We Recommend the Right Engagement
Scoped to your situation
Every company is different. Based on what we learn, we recommend the engagement that fits your stage, your needs, and your budget, from a focused protocol review to a full preclinical roadmap or ongoing advisory.
We Deliver
Presentation-ready output
You get presentation-ready deliverables: visual timelines, study-by-study budget tables, risk assessments, and executive summaries your board and investors can use directly.
Who We Work With
Early-stage biotech companies building preclinical programs in gene therapy, RNA therapeutics, biologics, and related modalities.
From Protocol Review to Fractional Leadership
Every engagement is scoped to what you actually need. Here are the most common starting points.
Protocol Review
Independent review before you commit to a CRO study.
Preclinical Diagnostic
Multidimensional program assessment with prioritized next-study recommendations.
Full Preclinical Roadmap
Study-by-study plans, biomarker strategy, CRO shortlists, and budget tables through IND-enabling.
Fractional Preclinical Leadership
Embedded in your team for strategy, CRO oversight, and milestone governance.
Plus investor readiness packages, IND writing, advisory, fractional leadership, and more.
Why BridgeLine
What makes the difference between a plan that holds up and one that doesn’t.
Operator-to-Acquirer Lens
Our founder has designed IND-enabling preclinical programs and evaluated early-stage companies from the acquirer’s side, supporting diligence on transactions valued up to $11B. The plans we build answer the questions investors and pharma BD teams actually ask.
Preclinical Depth
Every program is evaluated across multiple dimensions of preclinical readiness. Portfolio decisions are based on preclinical evidence, not abstract scoring. We also write the nonclinical sections of regulatory documents: Pre-IND briefing documents, IND Module 2.4, Module 2.6.
Presentation-Ready Deliverables
Visual timelines, study-by-study budget tables, and executive summaries, ready for board meetings, investor presentations, and data rooms. No translation layer needed.
Built to Reduce Your Risk
We structure engagements so you can move forward with confidence.
Trust Mechanics
- Clear scope, timeline, and pricing before you commit
- Satisfaction guarantee: 3+ actionable recommendations or full refund
- 100% diagnostic credit toward larger engagement
- Complimentary follow-up call after every diagnostic
- Presentation-ready deliverables with visual timelines and budget tables
What This Means in Practice
Built with an Operator-to-Acquirer Lens
BridgeLine combines hands-on execution experience with acquirer-side diligence perspective.
Timothy S. Luongo, PhD, MSTR
Founder and Principal
Experience spans Cephalon (now Teva), Sarepta Therapeutics, Spark Therapeutics (Roche), StrideBio, and the NIH. Designed and executed IND-enabling preclinical programs across gene therapy, RNA therapeutics, and biologics. Evaluated companies as acquisition/partnership targets and supported diligence on transactions valued up to $11B. PhD from Temple University. Master of Science in Translational Research (Regulatory Affairs and Drug Development) from UPenn. BS in Biochemistry from Eastern University. High-impact publication record including Nature, Cell, Immunity, and Circulation.
View LinkedIn ProfileTrusted by Leaders
Endorsements on rigor, decision quality, and execution.
“In my time working with Tim at Spark Therapeutics, he stood out for his ability to quickly identify what mattered most to reduce risk and keep teams focused on the highest-impact work. He translates complex data into clear priorities, crisp recommendations, and actionable next steps. He's highly collaborative and raises the quality of decision-making across functions. I would strongly recommend BridgeLine to any biotech building toward a key inflection point.”
Christopher Rilling, PhD
VP of Science, Parallel Bio
Ready to Build a Preclinical Plan That Holds Up?
Book a Strategy Call. Complimentary, 30 minutes, no obligation. We’ll discuss your program and recommend a practical next step.
Book a Strategy Call30-minute call · No obligation · Confidential
info@bridgelinetranslational.com · bridgelinetranslational.com